Summit Therapeutics (Summit Therapeutics) Debt-to-EBITDA : -0.80 (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Summit Therapeutics Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Summit Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $2.81 Mil. Summit Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $103.29 Mil. Summit Therapeutics's annualized EBITDA for the quarter that ended in Dec. 2023 was $-132.26 Mil. Summit Therapeutics's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.80.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Summit Therapeutics's Debt-to-EBITDA or its related term are showing as below:

SMMT' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -7.22 Med: -0.04 Max: 0.11
Current: -0.18

During the past 13 years, the highest Debt-to-EBITDA Ratio of Summit Therapeutics was 0.11. The lowest was -7.22. And the median was -0.04.

SMMT's Debt-to-EBITDA is ranked worse than
100% of 278 companies
in the Biotechnology industry
Industry Median: 1.375 vs SMMT: -0.18

Summit Therapeutics Debt-to-EBITDA Historical Data

The historical data trend for Summit Therapeutics's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Summit Therapeutics Debt-to-EBITDA Chart

Summit Therapeutics Annual Data

Trend

Jan14

Jan15

Jan16

Jan17

Jan18

Jan19

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

Get a 7-Day Free Trial

0.11

-0.01

-0.03

-7.22

-0.18

Summit Therapeutics Quarterly Data
	Jan19	Apr19	Jul19	Oct19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-EBITDA	Get a 7-Day Free Trial															-8.25	-0.05	-2.29	-1.49	-0.80

Competitive Comparison of Summit Therapeutics's Debt-to-EBITDA

For the Biotechnology subindustry, Summit Therapeutics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Summit Therapeutics's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Summit Therapeutics's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Summit Therapeutics's Debt-to-EBITDA falls into.

Summit Therapeutics Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Summit Therapeutics's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(2.809	+	103.29)	/	-596.417
	=	-0.18

Summit Therapeutics's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(2.809	+	103.29)	/	-132.26
	=	-0.80

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.

Summit Therapeutics (NAS:SMMT) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Summit Therapeutics Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Summit Therapeutics's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Summit Therapeutics (Summit Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Summit Therapeutics Inc (NAS:SMMT) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

2882 Sand Hill Road, Suite 106, Menlo Park, CA, USA, 94025

Website

https://www.smmttx.com

Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its lead CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.

Executives

Ankur Dhingra	officer: Chief Financial Officer	C/O CAREDX, INC., 1 TOWER PLACE, 9TH FLOOR, SOUTH SAN FRANCISCO CA 94080
Maky Zanganeh	director	51 ADAM WAY, ATHERTON CA 94027
Manmeet Singh Soni	director	C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE, SUNNYVALE CA 94085
Robert W Duggan	director, 10 percent owner, officer: See Remarks	611 SOUTH FORT HARRISON AVE, SUITE 306, CLEARWATER FL 33756
Yu Xia	director	6 SHENNONG ROAD, TORCH DEVELOPMENT ZONE, ZHONGSHAN, GUANGDONG F4 528437
Robert F. Booth	director	C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Alessandra Cesano	director	700 BALTIC CIRCLE, SUITE 716, REDWOOD CITY CA 94065
Urte Gayko	director	C/O PARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Kenneth A Clark	director	C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE., SUNNYVALE CA 94085
Jeffrey R Maranian	officer: VP, Corporate Controller	C/O SUMMIT THERAPEUTICS INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Luhua Wang	director	ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
David Jonathan Powell	officer: Chief Scientific Officer	ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Camilla Graham	officer: Chief Clinical Affairs Officer	ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Ventzislav Stefanov	director, officer: See Remarks	ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Ujwala Mahatme	director	ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142